A Novel Respiratory Syncytial Virus (RSV) F Subunit Vaccine Adjuvanted with GLA-SE Elicits Robust Protective TH1-Type Humoral and Cellular Immunity In Rodent Models

Vaccination with the RSV fusion protein formulated with a combination adjuvant induces long-lasting protective immunity

(2014) R. Garg et al.   JOURNAL OF GENERAL VIROLOGY

Targeting CD137 Enhances Vaccine-Elicited Anti-Respiratory Syncytial Virus CD8+ T Cell Responses in Aged Mice

(2013) S. Lee et al.   JOURNAL OF IMMUNOLOGY

IL-17A inhibits airway reactivity induced by respiratory syncytial virus infection during allergic airway inflammation

(2013) Dawn Catherine Newcomb et al.   THORAX

Adults 65 Years Old and Older Have Reduced Numbers of Functional Memory T Cells to Respiratory Syncytial Virus Fusion Protein

(2012) Anu Cherukuri et al.   Clinical and Vaccine Immunology

Molecular and Cellular Response Profiles Induced by the TLR4 Agonist-Based Adjuvant Glucopyranosyl Lipid A

(2012) Stacie L. Lambert et al.   PLoS One

Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention

(2012) M. Magro et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice

(2012) Anu Cherukuri et al.   Immunity & Ageing

IL-17–Induced Pulmonary Pathogenesis during Respiratory Viral Infection and Exacerbation of Allergic Disease

(2011) Sumanta Mukherjee et al.   AMERICAN JOURNAL OF PATHOLOGY

Particulate vaccines: on the quest for optimal delivery and immune response

(2011) Marie-Luce De Temmerman et al.   DRUG DISCOVERY TODAY

Respiratory syncytial virus vaccine development

(2011) Julia L Hurwitz   Expert Review of Vaccines

Evaluation of the Safety and Immunogenicity in Rhesus Monkeys of a Recombinant Malaria Vaccine for Plasmodium vivax with a Synthetic Toll-Like Receptor 4 Agonist Formulated in an Emulsion

(2011) Joanne M. Lumsden et al.   INFECTION AND IMMUNITY

GLA-SE, a Synthetic Toll-like Receptor 4 Agonist, Enhances T-Cell Responses to Influenza Vaccine in Older Adults

(2011) Hayedeh Behzad et al.   JOURNAL OF INFECTIOUS DISEASES

Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes

(2011) J. S. McLellan et al.   JOURNAL OF VIROLOGY

Phase 1 Study of the Safety and Immunogenicity of a Live, Attenuated Respiratory Syncytial Virus and Parainfluenza Virus Type 3 Vaccine in Seronegative Children

(2011) David I. Bernstein et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant

(2011) Rhea N. Coler et al.   PLoS One

Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers

(2011) K. A. Swanson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells

(2011) M. K. L. MacLeod et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Synthetic Adjuvant to Enhance and Expand Immune Responses to Influenza Vaccines

(2010) Rhea N. Coler et al.   PLoS One

Recombinant respiratory syncytial virus F protein expression is hindered by inefficient nuclear export and mRNA processing

(2010) Kelly Huang et al.   VIRUS GENES

Age related changes in T cell mediated immune response and effector memory to Respiratory Syncytial Virus (RSV) in healthy subjects

(2010) Maria Grazia Cusi et al.   Immunity & Ageing

Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations

(2009) Ryan C. Anderson et al.   COLLOIDS AND SURFACES B-BIOINTERFACES

Modulation of adaptive immunity with Toll-like receptors

(2009) Santhakumar Manicassamy et al.   SEMINARS IN IMMUNOLOGY

Role of lipopolysaccharide in the induction of type I interferon-dependent cross-priming and IL-10 production in mice by meningococcal outer membrane vesicles

(2009) Vanessa Durand et al.   VACCINE

A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults ≥65 years of age

(2009) Joanne M. Langley et al.   VACCINE

Enhanced humoral and Type 1 cellular immune responses with Fluzone® adjuvanted with a synthetic TLR4 agonist formulated in an emulsion

(2009) Susan L. Baldwin et al.   VACCINE

Antigen-nonspecific activation of CD8+ T lymphocytes by cytokines: relevance to immunity, autoimmunity, and cancer

(2008) Sheela Ramanathan et al.   ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS

Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus

(2008) Matthew R Olson et al.   Expert Review of Vaccines

Age-related decline in immunity: implications for vaccine responsiveness

(2008) Rajesh Kumar et al.   Expert Review of Vaccines

Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein

(2008) Teresa R. Johnson et al.   JOURNAL OF LEUKOCYTE BIOLOGY